Management of the psychotic substance using patient

CJAM Canadian Journal of Addiction Medicine

Volumn 5, Issue 2, 2014, Pages 5-9

  Balderston, Rhea ^a   Crockford, David N ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; OLANZAPINE; QUETIAPINE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; ZIPRASIDONE;

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR CHANGE; CANNABIS SMOKING; CASE REPORT; DRUG EFFICACY; HUMAN; MALE; MENTAL PERFORMANCE; OUTCOME ASSESSMENT; PARANOIA; PERSONAL HYGIENE; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; THOUGHT DISORDER; TREATMENT DURATION; YOUNG ADULT; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DEPENDENCE; FAMILY HISTORY; FOLLOW UP; HYGIENE; LANDSCAPING; LIFE; MENTAL DISEASE; MENTAL HEALTH; PARTTIME EMPLOYMENT; PLAY; PROBATION; SCHOOL ATTENDANCE; SMOKING; TELEVISION CAMERA; THREAT; VIDEO GAME; WRITING;

EID: 84903757584     PISSN: 19231210     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kovasznay B, Fleischer J, Tanenberg-Karant M. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23: 195-201.
2. Mauri M, Volonteri L, De Gaspari I, Colasanti A, Brambilla M, Cerruti L. Substance abuse in first-episode schizophrenic patients: A retrospective study. Clin Pract Epidemiol Ment Health 2006; 23: 2-4.
3. Reiger DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264: 2511-2518.
4. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous Delta-9- tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29(8): 1558-1572.
5. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM. The acute effects of synthetic intravenous Delta 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 39(10): 1607-1616.
6. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71: 37-48.
7. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-1486.
8. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100: 612-618.
9. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population- based study. Am J Epidemiol, 2002; 156: 319-327.
10. Henquet C Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330(7481): 11.
11. Arsenault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 2002; 325: 1212-1213.
12. Fergusson DM Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005; 100: 354-366.
13. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 2002; 114: 949-955.
14. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005; 19: 187-194.
15. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis? Can J Psychiatry 2006; 51: 556-565.
16. Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:467-497.
17. Menezes POR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P, Kuipers E. Drug and alcohol problems among individuals with severe mental illnesses in south London. Br J Psychiatry 1996; 168: 612-619.
18. Linszen DH, Dingemans PM, Lenior ME. Cannabis use and the course of recent onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279.
19. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: A powerful predictor of relapse in schizophrenia. Schizophr Res 1996; 20: 145-151.
20. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-290.
21. Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) 2006; 187: 229-236.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013: 110-111.
23. Clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 2005; 50 (suppl. 1): 1S-56S.
24. Data for the price of weed in: United Kingdom. Price of Weed: Global Price Index for Marijuana. www.priceofweed.com Retrieved August 3, 2013.
25. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, El-Sohly MA. Potency trends of ?9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55(5): 1209-1217.
26. Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (?-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5(1): 32-40.
27. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia- like symptoms in people who use cannabis. Br J Psychiatry 2008; 192(4): 306-7.
28. Björkenstam E, Björkenstam C, Hjern A, Reutfors J, Bodén R. A five year diagnostic follow-up of 1840 patients after a first episode non-schizophrenia and non-affective psychosis. Schizophr Res 2013 July 27 [Epub ahead of print].
29. Clark RE, Teague GB, Ricketts SK, Bush PW, Xie H, McGuire TG, Drake RE, McHugo GJ, Keller AM, Zubkoff M. Costeffectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Serv Res 1998; 33: 1285-1303.
30. Drake RE, Essock SM, Shaner A, Carey KB, Minkoff K, Kola L, Lynde D, Osher FC, Clark RE, Rickards L. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv 2000; 51: 1126-1129.
31. Psychosis with coexisting substance misuse, the NICE guideline on assessment and management in adults and young people. The British Psychological Society, Leicester, UK, and The Royal College of Psychiatrists, London, UK, 2011: 190-213.
32. Potvin S, Pampoulova T, Mancini-Marie A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006; 77: 796-798.
33. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002; 62: 743-755.
34. San L, Arranz B, Martinez-Raga J. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res 2007; 13: 230-243.
35. Tsuang JW, Eckman TE, Shaner A, Marder SR. Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry 1999; 156: 1119-1120.
36. Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:417-421.
37. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209-1223.
38. Mangrum LF, Spence RT, Lopez M. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. J Subst Abuse Treat 2006; 30(1): 79-84.
39. Wisdom JP, Manuel J, Drake RE. Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatr Serv 2011; 62(9): 1007-1012.
40. Drake RE, Caton CL, Xie H, Hsu E, Gorroochurn P, Samet S, Hasin DS. A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. Am J Psychiatry 2011; 168(7): 742-748.
41. Mueser KT, Drake RE, Noordsy DL. Integrated mental health and substance abuse treatment for severe psychiatric disorders. J Pract Psychiatry Behav Health 1998; 4: 129-139.